Investor Alert: Immunomedics, Inc. Investigation Announced by Holzer & Holzer, LLC
ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU) and/or certain of its officers complied with the federal securities laws when making statements to investors between May 9, 2013 and October 9, 2013. Specifically, the investigation focuses on statements issued by Immunomedics during that time regarding its relationship with Takeda Pharmaceutical Company and the development and commercialization of its drug Veltuzumab. On October 9, 2013, Immunomedics confirmed that its agreement with Takeda Pharmaceutical was terminated and the Company’s stock price fell on the news.
If you purchased Immunomedics common stock between May 9, 2013 and October 9, 2013 and suffered losses on that investment, you are encouraged to contact Holzer & Holzer, LLC and its attorney Marshall P. Dees, Esq. via email at email@example.com, or via toll-free telephone at (888) 508-6832 regarding your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.